A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.

Jeffrey A. Cohen,Michelle H. Cameron,Myla D. Goldman,Andrew D. Goodman,Aaron Miller,Anne Rollins,Lily Llorens,Rajiv Patni,Robert Elfont,Reed Johnson

A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.

2021

Jeffrey A. Cohen
Michelle H. Cameron
Myla D. Goldman
Andrew D. Goodman
Aaron Miller
Anne Rollins
Lily Llorens
Rajiv Patni
Robert Elfont
Reed Johnson

Background:ADS-5102, a delayed-release, extended-release (DR/ER) amantadine, improved walking speed in MS in a Phase 2 trial.Objective:The aim of this study was to present primary results of a Phas...

Keywords:

Randomized controlled trial
Placebo
Multiple sclerosis
double blind
Amantadine
extended release
Medicine
Physical medicine and rehabilitation
timed 25 foot walk
Preferred walking speed

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations